Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 12, 2010, Pages 1449-1457

  Francque, Sven ^a   Verrijken, An ^b   Mertens, Ilse ^b   Hubens, Guy ^a   Van Marck, Eric ^a   Pelckmans, Paul ^a   Van Gaal, Luc ^b   Michielsen, Peter ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Diabetes and Metabolism ^*  (Belgium)

Author keywords

human study; nonalcoholic fatty liver disease; portal hypertension

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; FEMALE; HEMODYNAMICS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER SINUSOID; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PREDICTOR VARIABLE; PRESSURE GRADIENT; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STEATOSIS;

ADULT; BELGIUM; BIOPSY; CATHETERIZATION; CHI-SQUARE DISTRIBUTION; FATTY LIVER; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; PORTAL PRESSURE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 78349313190     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833f14a1     Document Type: Article

References (64)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-140.
3. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993; 55:807-813.
4. Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant 2001; 15:53-57.
5. Behrns KE,Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2:292-298.
6. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21:105-113.
7. Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. Hepatology 1994; 20:1287-1293.
8. Hayashi M, Tokunaga Y, Fujita T, Tanaka K, Yamaoka Y, Ozawa K. The effects of cold preservation on steatotic graft viability in rat liver transplantation. Transplantation 1993; 56:282-287.
9. Rao MS, Papreddy K, Abecassis M, Hashimoto T. Regeneration of liver with marked fatty change following partial hepatectomy in rats. Dig Dis Sci 2001; 46:1821-1826.
10. Caraceni P, Domenicali M,Vendemiale G, Grattagliano I, Pertosa A, Nardo B, et al. The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. J Surg Res 2005; 124:160-168.
11. Selzner M, Rudiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 2000; 32:1280-1288.
12. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21:702-707.
13. Hakamada K, Sasaki M,Takahashi K, Umehara Y, Konn M. Sinusoidal flow block after warm ischemia in rats with diet-induced fatty liver. J Surg Res 1997; 70:12-20.
14. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999; 68:780-784.
15. Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transpl Surg 1998; 4:71-77.
16. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40:386-393.
17. Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis 2004; 36:406-411.
18. Mihmanli I, Kantarci F, Yilmaz MH, Gurses B, Selcuk D, Ogut G, et al. Effect of diffuse fatty infiltration of the liver on hepatic artery resistance index. J Clin Ultrasound 2005; 33:95-99.
19. Aoki T, Imamura H, Kaneko J, Sakamoto Y, Matsuyama Y, Kokudo N, et al. Intraoperative direct measurement of hepatic arterial buffer response in patients with or without cirrhosis. Liver Transpl 2005; 11:684-691.
20. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32:141-156.
21. Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE, et al. Functional significance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology2003; 37:385-392.
22. Lebrec D, Moreau R. Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol 2001; 13:309-311.
23. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005; 25:1079-1090.
24. Francque S, Wamutu S, Chatterjee S, Van Marck E, Herman A, Ramon A, et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int 2010; 30:365-375.
25. Puoti C, Bellis L. Steatosis and portal hypertension. Eur Rev Med Pharmacol Sci 2005; 9:285-290.
26. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873.
27. Obesity: Preventing and Managing The Global Epidemic. Report of a WHO consultation. Geneva: World Health Organization; 2000.
28. Van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993; 17:187-196.
29. Taylor KJ, Sullivan D, Simeone J, Rosenfield AT. Scintigraphy, ultrasound and CT scanning of the liver. Yale J Biol Med 1977; 50:437-455.
30. Merkel C, Bolognesi M, Bellon S, Bianco S, Honisch B, Lampe H, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33:836-842.
31. Farrell GC, George J, de la M, Hall P, McCullough AJ. An introduction to NASH and related fatty liver disorders. In: Farrell GC, George J, de la M, Hall P, McCullough AJ, editors. Fatty liver disease: NASH and related disorders. 1st ed. Massachusetts: Blackwell Publishing; 2005. pp. 1-12.
32. Cosgrove DO. Liver anatomy. In: Cosgrove D, Meire H, Dewbury K, editors. Abdominalandgeneralultrasound. 3rd ed. New York: Churchill Livingstone; 1994. pp. 227-242.
33. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132:112-117.
34. Dardenne AN. The spleen. In: Cosgrove D, Meire H, Dewbury K, editors. Abdominalandgeneralultrasound. 3rd ed. New York: Churchill Livingstone; 1994. pp. 351-366.
35. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266-1271.
36. Prati D, Taioli E, Zanella A, Della TE, Butelli S, Del VE, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med2002; 137:1-10.
37. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15:539-543.
38. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol 2003; 17:38-42.
39. Talwalkar JA. Motion-all patients with NASH need to have a liver biopsy: arguments for the motion. Can J Gastroenterol 2002; 16:718-721.
40. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004; 20:249-259.
41. Kalambokis G, Manousou P,Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy-indications, adequacy, quality of specimens, and complications-a systematic review. J Hepatol 2007; 47:284-294.
42. Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 1982; 83:338-340.
43. Groszmann R, Vorobioff JD, Gao H. Measurement of portal pressure: when, how, and why to do it. Clin Liver Dis 2006; 10:499-512.
44. Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis 2006; 26:348-362.
45. Lebrec D, Sogni P,Vilgrain V Evaluation of patientswith portal hypertension. Baillieres Clin Gastroenterol1997; 11:221-241.
46. Marino PL. The pulmonary artery catheter. In: Marino PL, editor. The ICU book. 2nd ed. Pennsylvania: Williams & Wilkins; 1998. pp. 154-165.
47. Kleiner DE, Brunt EM,Van NM, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
48. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457. (Pubitemid 37466971)
49. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-880.
50. Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007; 13:1305-1311.
51. Reynolds TB, Hidemura R, Michel H, Peters R. Portal hypertension without cirrhosis in alcoholic liver disease. Ann Intern Med 1969; 70:497-506.
52. Rockey DC Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10:459.
53. Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17:526-534.
54. Reynolds TB, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. Am J Med 1970; 49:649-657.
55. Farrell GC,Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. Anat Rec (Hoboken) 2008; 291:684-692.
56. Leclercq IA. Pathogenesis of steatohepatitis: insights from the study of animal models. Acta Gastroenterol Belg 2007; 70:25-31.
57. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27:412-421.
58. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46:582-589.
59. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89:221-231.
60. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenona? Diabetologia 2008; 51:1947-1953.
61. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-880.
62. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5:419-424.
63. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Haemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-908.
64. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol2006; 290:G980-G987.